Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L. Zambetti M, et al. Among authors: montemurro f. Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3. Eur J Cancer. 2018. PMID: 30396014 Clinical Trial.
Trastuzumab-based combination therapy for breast cancer.
Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Expert Opin Pharmacother. 2004 Jan;5(1):81-96. doi: 10.1517/14656566.5.1.81. Expert Opin Pharmacother. 2004. PMID: 14680438 Review.
TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.
Valabrega G, Montemurro F, Sarotto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. Valabrega G, et al. Among authors: montemurro f. Oncogene. 2005 Apr 21;24(18):3002-10. doi: 10.1038/sj.onc.1208478. Oncogene. 2005. PMID: 15735715
265 results